--- title: "UTHR CEO Rothblatt April 2026: Cashless Exercise Pattern" type: news slug: rothblatt-martine-uthr-april-2026-options-cashless-exercise canonical_url: https://13finsight.com/news/rothblatt-martine-uthr-april-2026-options-cashless-exercise published_at: 2026-05-06T14:21:05.931Z updated_at: 2026-05-06T14:21:08.792Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 885 locale: en source: 13F Insight --- # UTHR CEO Rothblatt April 2026: Cashless Exercise Pattern > Martine Rothblatt's April 2026 UTHR sales follow the M+S option-exercise + open-market sale pattern — a signature 10b5-1 cashless-exercise plan rather than a discretionary view-driven exit. Martine Rothblatt, Chairperson and CEO of United Therapeutics (UTHR), filed a fresh batch of Form 4 transactions on April 27-28, 2026, executing what the Form 4 record shows is one of the most active CEO selling patterns among large-cap specialty pharma. The most recent transactions report sales clustered around $566-$572 per share, with companion option-exercise (M-code) entries at strike prices around $146. Cumulative recorded transaction value across her trading history sits at $1.05 billion sold against $15.1 million purchased over 6,565 transactions. The story is not the size of any single April sale — most blocks fall in the $300K-$1.1M range — but the structural pattern: option exercise immediately followed by open-market sale. This is the signature of a long-running 10b5-1 plan that converts vested options into cash on a scheduled cadence, with the strike price and sale price together defining the per-share economic outcome. Rothblatt's career trading history shows the pattern recurring across multiple quarters, with the option-exercise + sale cluster timed to specific scheduled dates rather than discretionary windows. The Transaction Pattern Selected April 27, 2026 transactions illustrate the M+S sequence: 9,500 shares M-coded (option exercise) at strike $146.03 = $1.4M exercise cost 120 shares S-coded (open-market sale) at $572.22 = $69K 1,417 shares S-coded at $571.49 = $810K 1,653 shares S-coded at $570.57 = $943K 1,891 shares S-coded at $569.75 = $1.1M The pattern: exercise vested options at $146.03 strike, immediately sell the underlying shares in the open market across multiple price points within a single trading window. The economic outcome per share is the difference between the sale price and strike — approximately $420-$425 per share net per option exercised. This is the textbook signature of a 10b5-1 cashless-exercise plan, not a discretionary view-driven sale. Why the M+S Pattern Matters for Investor Read Three implications follow from the pattern: Not a discretionary exit. The exercise + sale sequence is locked to plan dates, with sale prices effectively whatever the market clearing price is at the scheduled execution time. Discretionary bearish framing on this kind of activity is factually wrong. The CEO retains operational alignment. Form 4 Table I after the latest sale shows 110,288 shares held directly. This is meaningfully smaller than the cumulative gross compensation Rothblatt has received over her tenure as CEO; the difference reflects the consistent M+S pattern over multiple years. Beneficial ownership cross-check is informative. Schedule 13G/A filings on UTHR show institutional holders approaching the 5% threshold (Wellington Management's February 2026 13G at 5.7%, Vanguard Capital Management's April 2026 13G at 5.19%) but no insider beneficial-ownership concentration that would suggest Rothblatt holds a controlling stake. The Specialty Pharma CEO Context Specialty pharma CEOs who run companies with binary clinical-readout and FDA-approval cadences typically execute pre-scheduled 10b5-1 plans precisely because discretionary trading windows are narrow and unpredictable. Rothblatt has run United Therapeutics through multiple major commercial launches (Tyvaso DPI inhalation, Remodulin, Adcirca) and Phase 3 readouts; the consistent M+S plan execution provides predictable diversification income while remaining compliant with the firm's blackout-window framework around earnings and clinical events. For institutional holders of UTHR — including Wellington Management's $2.4M-share 13G crossing in February 2026 — the Rothblatt M+S pattern is part of the equity's accepted ownership structure. Wellington's threshold-crossing 13G filing, which signals the firm has built past the 5% disclosure threshold, would not have been initiated if the institutional research desk viewed the CEO transaction pattern as a thesis-changing event. What the Sales Are Not Three framings should be avoided: "CEO dumping shares" framing. The M+S sequence is option-exercise followed by sale. The economic event is realization of pre-existing equity compensation, not a discretionary view-driven exit. "Insider selling signals top" framing. Rothblatt has been executing this M+S pattern across multiple quarters and multiple share-price levels. The sales correlate with plan dates, not with valuation peaks. "CEO loss of confidence" framing. Routine 10b5-1 cashless-exercise plans are the standard approach for specialty pharma CEOs balancing compliance constraints with personal portfolio diversification needs. The 13D/G Cross-Check UTHR's beneficial-ownership tape shows two recent institutional 13G threshold crossings worth noting: Wellington Management Group filed Schedule 13G on February 10, 2026 disclosing 5.7% beneficial ownership of 2,441,492 shares. Vanguard Capital Management filed Schedule 13G on April 30, 2026 disclosing 5.19% beneficial ownership of 2,278,348 shares. The Wellington crossing is the more informative signal: Wellington's healthcare research desk runs deep diligence on specialty pharma names and is sized to drive material flow when initiated at the 5%+ threshold. The April Vanguard crossing reflects index-fund mechanical accumulation and does not signal active conviction. Investors can verify directly via SEC EDGAR's 13D/G page for United Therapeutics (CIK 0001082554) and the Form 4 history for CIK 0001106578. The Forward Read For investors using Form 4 data on Martine Rothblatt's United Therapeutics transactions: Treat the M+S sequence as plan-driven execution noise. Discretionary view changes would show in materially different volume patterns, typically clustered around earnings or clinical events outside the plan window. The Wellington 5.7% 13G crossing is the more actionable signal on UTHR positioning. Watch for follow-on Wellington filings (13G/A amendments) over the next 4-6 quarters. The 110,288 shares Rothblatt holds directly post the latest sale represents her residual operational alignment, not a controlling stake; UTHR's governance structure does not depend on insider beneficial ownership concentration. See Martine Rothblatt's full Form 4 transaction history on 13F Insight → ## FAQ ### Why is Martine Rothblatt selling United Therapeutics shares? The April 2026 sales follow the consistent option-exercise + sale (M+S) pattern that signals 10b5-1 plan execution. Rothblatt exercises vested options at strike $146.03 and immediately sells the underlying shares in the open market — a textbook cashless-exercise plan, not a discretionary view-driven exit. ### How much United Therapeutics stock does Martine Rothblatt own? Per the latest Form 4, Rothblatt holds 110,288 shares directly after the April 27-28 sales. Schedule 13G/A filings do not show Rothblatt holding a controlling beneficial stake; UTHR's governance structure does not depend on insider ownership concentration. ### What does the M+S transaction pattern mean? M+S is the standard signature of a 10b5-1 cashless-exercise plan: M-code transactions are option exercises (typically at low strike prices), immediately followed by S-code open-market sales of the underlying shares. The economic outcome per share is the difference between sale price and strike — approximately $420-$425 per share for the April execution. ### Are there activist 13D filings on United Therapeutics? No. The recent 13D/G activity on UTHR is limited to institutional Schedule 13G threshold crossings — Wellington Management at 5.7% (February 2026) and Vanguard Capital Management at 5.19% (April 2026). The Wellington filing is the more informative active-conviction signal. ### Where can I verify Rothblatt's Form 4 filings? SEC EDGAR's Form 4 history for CIK 0001106578 contains all filings. The 13D/G beneficial-ownership tape for United Therapeutics is at the 13D/G search page for CIK 0001082554. Both pages are public and free to access. --- Source: 13F Insight — https://13finsight.com/news/rothblatt-martine-uthr-april-2026-options-cashless-exercise Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-06T14:21:08.792Z